Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice
Repurposing of drugs is a strategy for discovering new uses for already authorized or tested medicines outside their original indications. Bevacizumab is humanized antibody, observed to have anti-VEGF (Vascular Endothelial Growth Factor) effect, which is indicated for colorectal, lung and other type...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Biotechnology & Biotechnological Equipment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13102818.2024.2357191 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850106097903337472 |
|---|---|
| author | Antonio Ivanov Violeta Getova-Kolarova Valentina Belcheva Evgeni Grigorov Ilko Getov |
| author_facet | Antonio Ivanov Violeta Getova-Kolarova Valentina Belcheva Evgeni Grigorov Ilko Getov |
| author_sort | Antonio Ivanov |
| collection | DOAJ |
| description | Repurposing of drugs is a strategy for discovering new uses for already authorized or tested medicines outside their original indications. Bevacizumab is humanized antibody, observed to have anti-VEGF (Vascular Endothelial Growth Factor) effect, which is indicated for colorectal, lung and other types of carcinomas. We conducted research on the historical development and current regulatory status of bevacizumab. In addition, analysis of the data on completed clinical trials with bevacizumab showing potential for repurposing was performed. The analysis for the period 01.01.2019-31.12.2022 found 131 trials, 42 (32%) of which have potential for repurposing. The development and influence of bevacizumab-biosimilar medicines was studied in the whole clinical trials database with biosimilars included in 23 trials (15 in Phase I and 8 in Phase III). The performed research and analysis show that bevacizumab with its pharmacological mechanism of action can affect crucial point in the pathogenesis of different diseases. In addition to this, the process of repurposing can discover new pathways of treatment for patients, shorten the time for reaching the market, lower public healthcare expenses and companies’ budgets. With all the results pointed out, this biotechnological product has potential for repurposing in broad spectrum of new indications. |
| format | Article |
| id | doaj-art-7e1c5be074a54b9a8e9162907355c939 |
| institution | OA Journals |
| issn | 1310-2818 1314-3530 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Biotechnology & Biotechnological Equipment |
| spelling | doaj-art-7e1c5be074a54b9a8e9162907355c9392025-08-20T02:38:55ZengTaylor & Francis GroupBiotechnology & Biotechnological Equipment1310-28181314-35302024-12-0138110.1080/13102818.2024.2357191Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practiceAntonio Ivanov0Violeta Getova-Kolarova1Valentina Belcheva2Evgeni Grigorov3Ilko Getov4Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaDepartment of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaDepartment of Pharmaceutical Sciences, Medical College, Trakia University-Stara Zagora, Stara Zagora, BulgariaDepartment of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University “Prof. Dr. Paraskev Stoyanov”-Varna, Varna, BulgariaDepartment of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaRepurposing of drugs is a strategy for discovering new uses for already authorized or tested medicines outside their original indications. Bevacizumab is humanized antibody, observed to have anti-VEGF (Vascular Endothelial Growth Factor) effect, which is indicated for colorectal, lung and other types of carcinomas. We conducted research on the historical development and current regulatory status of bevacizumab. In addition, analysis of the data on completed clinical trials with bevacizumab showing potential for repurposing was performed. The analysis for the period 01.01.2019-31.12.2022 found 131 trials, 42 (32%) of which have potential for repurposing. The development and influence of bevacizumab-biosimilar medicines was studied in the whole clinical trials database with biosimilars included in 23 trials (15 in Phase I and 8 in Phase III). The performed research and analysis show that bevacizumab with its pharmacological mechanism of action can affect crucial point in the pathogenesis of different diseases. In addition to this, the process of repurposing can discover new pathways of treatment for patients, shorten the time for reaching the market, lower public healthcare expenses and companies’ budgets. With all the results pointed out, this biotechnological product has potential for repurposing in broad spectrum of new indications.https://www.tandfonline.com/doi/10.1080/13102818.2024.2357191Bevacizumabrepurposingclinical trialsbiosimilars |
| spellingShingle | Antonio Ivanov Violeta Getova-Kolarova Valentina Belcheva Evgeni Grigorov Ilko Getov Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice Biotechnology & Biotechnological Equipment Bevacizumab repurposing clinical trials biosimilars |
| title | Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice |
| title_full | Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice |
| title_fullStr | Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice |
| title_full_unstemmed | Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice |
| title_short | Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice |
| title_sort | research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice |
| topic | Bevacizumab repurposing clinical trials biosimilars |
| url | https://www.tandfonline.com/doi/10.1080/13102818.2024.2357191 |
| work_keys_str_mv | AT antonioivanov researchandpilotanalysisofbevacizumabrepurposingpotentialanditsimpactinclinicalpractice AT violetagetovakolarova researchandpilotanalysisofbevacizumabrepurposingpotentialanditsimpactinclinicalpractice AT valentinabelcheva researchandpilotanalysisofbevacizumabrepurposingpotentialanditsimpactinclinicalpractice AT evgenigrigorov researchandpilotanalysisofbevacizumabrepurposingpotentialanditsimpactinclinicalpractice AT ilkogetov researchandpilotanalysisofbevacizumabrepurposingpotentialanditsimpactinclinicalpractice |